

Masked polycythemia vera: analysis of a single center cohort of 2480 red cell masses

Nabih Maslah,^{*1,2,3,4} Juliette Soret,^{*2,5} Christine Dosquet,^{1,2,4} Laetitia Vercellino,⁶ Célia Belkhodja,^{1,2} Marie-Hélène Schlageter,^{1,2,4} Bruno Cassinat,^{1,2,4} Jean-Jacques Kilandjian,^{2,3,4,5} Christine Chomienne^{1,2,3,4} and Stéphane Giraudier^{1,2,3,4}

*These authors are co-first authors.

¹APHP, Hôpital Saint Louis, Service de Biologie Cellulaire; ²France Intergroupe des syndromes Myéloprolifératifs (FIM); ³Université Paris-Diderot; ⁴INSERM U1131, Centre Hayem, Hôpital Saint Louis; ⁵APHP, Hôpital Saint Louis, Centre d'Investigations Cliniques and ⁶APHP, Hôpital Saint Louis, Service de Médecine Nucléaire, Paris, France

Correspondence: STEPHANE GIRAUDIER - stephane.giraudier@aphp.fr

doi:10.3324/haematol.2018.215582

	JAK2 negative	JAK2 positive	p
n=	999	469	
Age (years) (mean, standard error)	55.15 +/-15.9	59.6 +/-6.52	<0.001
WBC ($10^9/L$)	7.5 +/-3.46	10.38 +/-14.37	<0.001
Hb (g/dl)	17.16 +/-1.56	16.22 +/-3.4	<0.001
Ht (%)	49.9 +/-4.51	48.7 +/-15.47	<0.001
MCV (fl)	88.5 +/-6	85.6 +/-7	<0.001
Platelet($10^9/L$)	245 +/-176	541 +/-146	<0.001
RCM (% of normal)	125.4 +/-17.4	138.9 +/-29.3	<0.001
RCM > +125%	52.3%	62.6%	<0.001
Plasma Vol (+%)	94.7+/-12.45	105.1 +/-34.6	<0.001
Epo (mUI/ml)	12.54 +/-35.33	4.90 +/-34.66	<0.001

Platelet count	ET	mPV	PV
> 500	54.5%	63.7%	30%
>600	41.8%	43.3%	19.6%
>1000	3.6%	2.6%	2.5%

	Plasma Volumes	With spleen enlargement	Without spleen enlargement
PV	Mean Plasma Volume	98,4%	95,4%
	% of Plasma volume>110%	26,6%	11%
mPV	Mean Plasma Volume	112,1%	104,3%
	% of Plasma volume>110%	53,3%	37%
ET	Mean Plasma Volume	96,2%	92,6%
	% of Plasma volume>110%	0%	3,3%

Supplementary Table 3. Maslah et al.

Ht (%)	n	% with RCM >125%
<35	9	11%
35-40	14	14%
40-42	23	43%
42-45	83	31%
45-47	59	58%
47-49	67	67%
49-51	51	72.5%
51-53	47	74.5%
53-55	34	91%
55-57	26	100%
57-60	22	95.5%
>60	25	100%

Supplementary Table 1: Characteristics of JAK2V617F positive and negative patients in the center.

JAK2V617F determination and RCM measurement were done the same day.

Supplementary Table 2: Frequencies of ET, masked PV and overt PV patients according to platelets levels over 500, 600 or 1000 G/L in the analyzed cohort.

Supplementary Table 3: Mean plasmatic volume and frequencies of Plasma volume increased over 110% in PV, mPV and ET patients with or without spleen enlargement.

Supplementary Table 4: Frequencies of RCM>125% according to Hematocrit level in JAK2V617F positive patients.